BIOMAT Database Logo BIOMAT Database Logo

Response of prostate-specific antigen after androgen withdrawal and prognosis in men with metastatic prostate cancer. 1998

Y Furuya, and S Akimoto, and K Akakura, and T Igarashi, and S Murakami, and J Shimazaki, and H Ito
Department of Urology, Chiba University, School of Medicine, Asahi General Hospital, Chiba, Japan.

OBJECTIVE Patients with prostate cancer generally respond to androgen withdrawal therapy, but progression to androgen independence is frequently observed. To evaluate prognostic factors in metastatic prostate cancer, patients who had been treated with endocrine therapy were investigated. METHODS One hundred and thirty-nine patients with untreated metastatic prostate cancer (TxNxM1) who received endocrine therapy between 1986 and 1993 were included in the present study. Blood chemistry, histological grade, extent of bony metastases, clinical response to hormone therapy, and the prognosis of the patients were evaluated. RESULTS With univariate analysis, performance status, hemoglobin concentration, serum alkaline phosphatase, lactate dehydrogenase, histological grade, extent of bony disease, and response of prostate-specific antigen (PSA) at 3 months were shown to be significant prognostic factors. With multivariate analyses, response of PSA and histological grade were significant factors predicting prognosis. CONCLUSIONS Patients whose PSA had not normalized 3 months after the start of endocrine therapy were in the high-risk group, and should be given more aggressive treatment.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009362 Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. Metastase,Metastasis,Metastases, Neoplasm,Metastasis, Neoplasm,Neoplasm Metastases,Metastases
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D001774 Blood Chemical Analysis An examination of chemicals in the blood. Analysis, Blood Chemical,Chemical Analysis, Blood,Analyses, Blood Chemical,Blood Chemical Analyses,Chemical Analyses, Blood
D001859 Bone Neoplasms Tumors or cancer located in bone tissue or specific BONES. Bone Cancer,Cancer of Bone,Cancer of the Bone,Neoplasms, Bone,Bone Neoplasm,Neoplasm, Bone
D002715 Chlormadinone Acetate An orally active synthetic progestational hormone used often in combinations as an oral contraceptive (CONTRACEPTIVES, ORAL). Pregna-4,6-diene-3,20-dione, 17-(acetyloxy)-6-chloro-,Chlormadinon Acetate,Chlormadinone,Chlormadinone Acetate, (9 beta,10 alpha)-Isomer,Neo-Eunomin,Neo Eunomin,NeoEunomin
D004054 Diethylstilbestrol A synthetic nonsteroidal estrogen used in the treatment of menopausal and postmenopausal disorders. It was also used formerly as a growth promoter in animals. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), diethylstilbestrol has been listed as a known carcinogen. (Merck, 11th ed) Stilbestrol,Agostilben,Apstil,Diethylstilbestrol, (Z)-Isomer,Diethylstilbestrol, Disodium Salt,Distilbène,Stilbene Estrogen,Tampovagan,Estrogen, Stilbene

Related Publications

Y Furuya, and S Akimoto, and K Akakura, and T Igarashi, and S Murakami, and J Shimazaki, and H Ito
Prognostic significance of changes in short-term prostate volume and serum prostate-specific antigen after androgen withdrawal in men with metastatic prostate cancer.
January 2003, Urologia internationalis,
Y Furuya, and S Akimoto, and K Akakura, and T Igarashi, and S Murakami, and J Shimazaki, and H Ito
Prostate-specific antigen nadir and time to prostate-specific antigen nadir following maximal androgen blockade independently predict prognosis in patients with metastatic prostate cancer.
September 2012, Korean journal of urology,
Y Furuya, and S Akimoto, and K Akakura, and T Igarashi, and S Murakami, and J Shimazaki, and H Ito
Prostate-specific antigen decline after gonadotropin-releasing hormone antagonist withdrawal in androgen-independent prostate cancer.
April 2005, Urology,
Y Furuya, and S Akimoto, and K Akakura, and T Igarashi, and S Murakami, and J Shimazaki, and H Ito
Prostate specific antigen after gonadal androgen withdrawal and deferred flutamide treatment.
August 1995, The Journal of urology,
Y Furuya, and S Akimoto, and K Akakura, and T Igarashi, and S Murakami, and J Shimazaki, and H Ito
Prostate specific antigen regression and progression after androgen deprivation for localized and metastatic prostate cancer.
June 1995, The Journal of urology,
Y Furuya, and S Akimoto, and K Akakura, and T Igarashi, and S Murakami, and J Shimazaki, and H Ito
Prostate-specific antigen kinetics under androgen deprivation therapy and prostate cancer prognosis.
January 2013, Urologia internationalis,
Y Furuya, and S Akimoto, and K Akakura, and T Igarashi, and S Murakami, and J Shimazaki, and H Ito
RE: Prostate specific antigen after gonadal androgen withdrawal and deferred flutamide treatment.
May 1996, The Journal of urology,
Y Furuya, and S Akimoto, and K Akakura, and T Igarashi, and S Murakami, and J Shimazaki, and H Ito
RE: Prostate specific antigen after gonadal androgen withdrawal and deferred flutamide treatment.
May 1996, The Journal of urology,
Y Furuya, and S Akimoto, and K Akakura, and T Igarashi, and S Murakami, and J Shimazaki, and H Ito
Prostate specific antigen half-time and prostate specific antigen doubling time as predictors of response to androgen deprivation therapy for metastatic prostate cancer.
June 2009, The Journal of urology,
Y Furuya, and S Akimoto, and K Akakura, and T Igarashi, and S Murakami, and J Shimazaki, and H Ito
Prostate-specific antigen doubling time predicts response to deferred antiandrogen therapy in men with androgen-independent prostate cancer.
April 2004, Urology,
Copied contents to your clipboard!